Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB756050 is a specific TGR5 agonist.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 8,000 | |||
10 mg | 在庫あり | ¥ 13,500 | |||
25 mg | 在庫あり | ¥ 25,000 | |||
50 mg | 在庫あり | ¥ 41,000 | |||
100 mg | 在庫あり | ¥ 66,000 | |||
500 mg | 在庫あり | ¥ 157,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 9,000 |
説明 | SB756050 is a specific TGR5 agonist. |
In vitro | TGR5 is a potential target for the therapy of type 2 diabetes (T2D). Thus, SB756050 is used in phase 1clinical trials for the treatment of type 2 diabetes. |
In vivo | SB756050 is well‐tolerated with nonlinear pharmacokinetics. It shows dose‐proportional increase in plasma exposure above 100 mg, and has no marked changes in exposure when co‐administered with sitagliptin. SB756050 has highly variable pharmacodynamic effects both within between doses and dose groups, with increases in glucose seen at the two lowest doses and no reduction in glucose seen at the two highest doses. The glucose effects of SB756050 t sitagliptin are comparable to those of sitagliptin alone, even though gut hormone plasma profiles are different. |
別名 | SB-756050, SB 756050 |
分子量 | 500.59 |
分子式 | C21H28N2O8S2 |
CAS No. | 447410-57-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (109.87 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SB756050 447410-57-3 GPCR/G Protein GPCR19 G protein-coupled Bile Acid Receptor 1 inhibit TGR5 Inhibitor SB-756050 GPBAR1 G-protein coupled receptor 19 SB 756050 inhibitor